Will a GLP-1 help my mood or anxiety?

Possibly, but the evidence is early. Observational data and small studies have suggested less anxiety and modestly better mood for some patients, likely tied to lower inflammation and quieter reward-circuit activity. GLP-1s are not approved for depression or anxiety, and a primary mental-health treatment plan should still come first.

Can I lose libido on a GLP-1?

Yes, some patients do report lower libido on GLP-1 medications, often as part of the broader emotional flattening some experience. Not everyone does. If it happens to you, it is worth raising; titration, dose adjustment, or stepping off can often bring it back.

Are these brain effects reversible?

In adults, most of the effects of GLP-1s, including weight changes, appear to be largely reversible once the medication is stopped. The brain effects appear to follow the same pattern, but the data is still early. In adolescents, whose brains are still developing, the long-term picture is much less clear, and these medications are used more cautiously.

Should I worry about brain fog on a GLP-1?

Brain fog is sometimes reported but is not a consistent finding. When it shows up, it is often related to dehydration, low calorie intake during rapid weight loss, or under-eating protein. Most cases improve with better nutrition and a slower titration. If brain fog persists despite those fixes, raise it with your doctor.

How might GLP-1s affect the brain's reward circuit?

GLP-1s appear to modulate the dopamine-driven reward system that decides what is worth seeking. By quieting that system, the medications may reduce craving for food, alcohol, nicotine, and other reward triggers. The same mechanism can also reduce the pull of healthier rewards like exercise, music, or intimacy, which is the leading explanation for the emotional flattening some patients describe.

What is the role of the vagus nerve in the GLP-1 story?

The vagus nerve is the long signaling pathway between the gut and the brain stem. Naturally produced GLP-1 talks to the brain through this nerve, helping regulate hunger, fullness, mood, and craving. GLP-1 medications appear to act on the same pathway, which is one reason their effects extend beyond pure appetite suppression.

Why are GLP-1s being studied for long covid and inflammation-driven brain symptoms?

Persistent inflammation appears to play a role in the cognitive symptoms many people still report years after a covid-19 infection. GLP-1 medications reduce several markers of systemic and neuroinflammation in early studies, which is the rationale for testing tirzepatide and similar agents in long covid trials now underway.

What is the relationship between GLP-1s and PMOS?

PMOS (formerly known as PCOS) is a multisystem hormonal and metabolic condition where GLP-1 medications can help by quieting metabolic dysfunction. The University of Colorado study used GLP-1s in adolescents with PMOS and observed brain connectivity changes alongside the metabolic improvements. See our PMOS article for the broader picture.

What is the off-ramp strategy you use with members?

The off-ramp depends on the patient and the goal. For weight maintenance, we titrate down to the lowest effective dose, often pairing it with intensified resistance training and protein. For acute uses like alcohol craving reduction, we set a defined window with a planned stop. The principle is the same as any chronic medication: no plan is its own plan, and that is the one we avoid.

How do you decide when to stop a GLP-1 for brain reasons?

When the brain side is interfering with the life the patient wants to live - libido, motivation, pleasure, relationships - and lower doses have not resolved it. We typically try a titration step down first, and if the brain effects do not improve, we step off and rely on the lifestyle work that has built up underneath. The medication is a tool the patient can set down.

Why is Philadelphia's metabolic-medicine landscape relevant here?

GLP-1s have been prescribed casually in many parts of primary care across the country, including locally, often without the kind of titration plan, muscle protection, or brain monitoring this article describes. Direct primary care gives us time to do this right: define the goal, watch for the brain side, protect muscle, and plan the off-ramp. Every careful prescription is a small local win.

Will a GLP-1 help my mood or anxiety?

Possibly, but the evidence is early. Observational data and small studies have suggested less anxiety and modestly better mood for some patients, likely tied to lower inflammation and quieter reward-circuit activity. GLP-1s are not approved for depression or anxiety, and a primary mental-health treatment plan should still come first.

Can I lose libido on a GLP-1?

Yes, some patients do report lower libido on GLP-1 medications, often as part of the broader emotional flattening some experience. Not everyone does. If it happens to you, it is worth raising; titration, dose adjustment, or stepping off can often bring it back.

Are these brain effects reversible?

In adults, most of the effects of GLP-1s, including weight changes, appear to be largely reversible once the medication is stopped. The brain effects appear to follow the same pattern, but the data is still early. In adolescents, whose brains are still developing, the long-term picture is much less clear, and these medications are used more cautiously.

Should I worry about brain fog on a GLP-1?

Brain fog is sometimes reported but is not a consistent finding. When it shows up, it is often related to dehydration, low calorie intake during rapid weight loss, or under-eating protein. Most cases improve with better nutrition and a slower titration. If brain fog persists despite those fixes, raise it with your doctor.

How might GLP-1s affect the brain's reward circuit?

GLP-1s appear to modulate the dopamine-driven reward system that decides what is worth seeking. By quieting that system, the medications may reduce craving for food, alcohol, nicotine, and other reward triggers. The same mechanism can also reduce the pull of healthier rewards like exercise, music, or intimacy, which is the leading explanation for the emotional flattening some patients describe.

What is the role of the vagus nerve in the GLP-1 story?

The vagus nerve is the long signaling pathway between the gut and the brain stem. Naturally produced GLP-1 talks to the brain through this nerve, helping regulate hunger, fullness, mood, and craving. GLP-1 medications appear to act on the same pathway, which is one reason their effects extend beyond pure appetite suppression.

Why are GLP-1s being studied for long covid and inflammation-driven brain symptoms?

Persistent inflammation appears to play a role in the cognitive symptoms many people still report years after a covid-19 infection. GLP-1 medications reduce several markers of systemic and neuroinflammation in early studies, which is the rationale for testing tirzepatide and similar agents in long covid trials now underway.

What is the relationship between GLP-1s and PMOS?

PMOS (formerly known as PCOS) is a multisystem hormonal and metabolic condition where GLP-1 medications can help by quieting metabolic dysfunction. The University of Colorado study used GLP-1s in adolescents with PMOS and observed brain connectivity changes alongside the metabolic improvements. See our PMOS article for the broader picture.

What is the off-ramp strategy you use with members?

The off-ramp depends on the patient and the goal. For weight maintenance, we titrate down to the lowest effective dose, often pairing it with intensified resistance training and protein. For acute uses like alcohol craving reduction, we set a defined window with a planned stop. The principle is the same as any chronic medication: no plan is its own plan, and that is the one we avoid.

How do you decide when to stop a GLP-1 for brain reasons?

When the brain side is interfering with the life the patient wants to live - libido, motivation, pleasure, relationships - and lower doses have not resolved it. We typically try a titration step down first, and if the brain effects do not improve, we step off and rely on the lifestyle work that has built up underneath. The medication is a tool the patient can set down.

Why is Philadelphia's metabolic-medicine landscape relevant here?

GLP-1s have been prescribed casually in many parts of primary care across the country, including locally, often without the kind of titration plan, muscle protection, or brain monitoring this article describes. Direct primary care gives us time to do this right: define the goal, watch for the brain side, protect muscle, and plan the off-ramp. Every careful prescription is a small local win.

Ozempic and Your Brain: What GLP-1s Do Beyond Weight Loss

TL;DR30-second take

GLP-1 medications were built for blood sugar and weight, and they do those jobs well. The newer story is the brain. Many patients describe a dramatic quieting of "food noise," and emerging research suggests the same circuits that quiet hunger may also dampen reward, craving, and emotional intensity more broadly. Some patients welcome that effect (less alcohol, less compulsive eating, less anxious rumination). Others describe a flatter version of themselves - lower libido, less pleasure from hobbies, less spark. The science is early. Trials in Alzheimer's have not yet shown clinical benefit; trials in alcohol and nicotine use disorder are underway and look promising. The right approach is to use these medications deliberately, pair them with strength training and protein, and watch for changes that go beyond the scale. If the brain side does not fit your life, we titrate down or step off.

GLP-1 medications were supposed to be a gut story. Then patients started reporting other things. Less interest in their nightly drink. Less pull toward the things they used to crave. Less anxiety, less ruminating. And, in some, less of everything: less pleasure from food, less interest in sex, a flatter emotional baseline.

Tens of millions of people are now on these drugs worldwide. What started as a metabolic breakthrough has slowly become one of the largest unintended neuroscience experiments in modern medicine. The honest version of the story is that we know enough to be careful and excited at the same time.

For the cardiometabolic side of the story, read GLP-1 medications beyond weight loss. For the broader prescribing lens, see how I decide to prescribe.

What we already knew: the "food noise" effect

The first surprise had less to do with weight than with quiet.

Patients on semaglutide and tirzepatide kept describing the same thing in different words: the constant background pull toward eating, the loop of "what is next, am I hungry, what is in the fridge," just went away. Researchers started calling it food noise, and it has held up across thousands of patient interviews. The drugs do more than blunt appetite. They turn down the brain circuit that obsesses about food in the first place.

That alone reframed what these medications are. They are not appetite suppressants in the older, blunt sense. They modulate hunger and craving signaling - hormones like GLP-1 and GIP, with receptors in the gut, the brain stem, the hypothalamus, and the reward system. They act on the vagus nerve, the long gut-to-brain pathway that helps decide what is rewarding and what is not.

That fact alone predicted what came next.

What's emerging now: reward, craving, mood

If the medications quiet the urge to seek food, they might quiet other things people seek too.

The early evidence points that way, in ways that cut both directions.

The hopeful side

Alcohol. Early animal work in 2013 showed rodents on a GLP-1-like medication drank less alcohol. Human trials are now underway. Eli Lilly has a large clinical trial of tirzepatide for alcohol use disorder expected to read out within the next year. Patients on the medications informally report the same change: the nightly drink loses its pull.
Nicotine, gambling, binge eating. Trials are running across each of these. The mechanism is the same circuit: a reward system that has been hijacked by a substance or behavior, and a medication that quiets the hijack.
Mood and anxiety signals. Observational data and small studies have hinted that some patients feel less anxious, less compulsive, and a step less depressed. These signals are worth watching but preliminary, and randomized trials in psychiatric conditions are still early.
Long covid and inflammation. Trials of tirzepatide in long covid are underway on the hypothesis that chronic inflammation is part of the brain symptoms. We do not have the answer yet.

The cautionary side

Patients also report a less welcome version of the same effect. The blanket term in social media and patient communities is "Ozempic personality." It tends to mean some combination of:

A flatter baseline mood, with less spark and less spontaneous joy, though it stops short of depression.
Reduced pleasure from hobbies, music, food beyond hunger, or other reliable rewards.
Lower libido.
Less motivation to chase the things that used to feel meaningful.

Not everyone experiences this. Many patients describe the opposite: the food noise quieting lets the rest of life back in. But the reports are common enough, and the underlying mechanism plausible enough, that "watch for emotional flattening" is part of how I talk to patients before they start.

How the brain effects probably work

We are still in the early innings on the mechanism, and several plausible explanations are likely true at the same time.

Direct brain action. GLP-1 receptors are densely concentrated in the hypothalamus, the brain stem, and parts of the reward circuit. Even though GLP-1 medications are large molecules, enough of them appears to reach the brain to act there.
Indirect brain action through the gut. Naturally produced GLP-1 talks to the brain through the vagus nerve. The same circuit modulates appetite, craving, mood, and cognition.
Inflammation, lowered. Some of the benefit may come from quieter system-wide inflammation. Brain inflammation has been implicated in cognitive decline, mood disorders, and the "brain fog" people describe after illness. GLP-1s appear to reduce some inflammatory markers.
Neuroplasticity changes. Early imaging studies have found increased connectivity in networks like the salience network (the system that decides what is worth paying attention to) in patients on these medications. The clinical meaning is still unclear.

The best summary is that GLP-1s appear to nudge the brain's reward and salience machinery. That is good news when the system is stuck on alcohol, food, or compulsive thoughts. It is more complicated when the system is healthy and the medication blunts the things you want to feel.

What the big trials have and have not shown

Fishtown Medicine

A 90-minute conversation with Dr. Ash. A written plan you can actually follow.

Start your intake

The biggest scientific question of 2025 was whether GLP-1s could slow Alzheimer's disease. The answer, at least in the first large readout, was disappointing.

Novo Nordisk's Phase III evoke trials of oral semaglutide in early Alzheimer's did not meet their primary endpoint. The medication did not significantly slow cognitive decline at the doses and timepoints tested. For many observers, that closed one of the most ambitious doors.

But it did not close the door on the brain story. Deeper in the same data, modest signals appeared in cerebrospinal fluid biomarkers tied to neuroinflammation and neurodegeneration. Earlier imaging studies had also suggested GLP-1s might slow loss of brain volume in regions tied to memory and planning.

Several leading Alzheimer's researchers now think the trial may have been run too late in the disease course. The same question is being asked in Parkinson's, where early animal work was promising and a recent clinical trial in established disease was negative. Researchers are now testing whether higher doses and earlier patients could change the picture.

The honest read for now: GLP-1s do something to the aging brain, but we do not yet have evidence they treat Alzheimer's or Parkinson's after the diseases have set in. Whether they delay or prevent them is a different question that the field is still working on.

What I want you to know

When I prescribe a GLP-1, the conversation covers the whole life around the medication, well beyond the scale. A short version of how I think about it:

The medication is a tool. The job is to quiet a hijacked signal and let you do the work you could not do before. If you feel like a different person on it, in a direction you do not want, that is worth a conversation. We can usually titrate or step off.
Watch for emotional flattening. If pleasure from hobbies, music, food beyond hunger, or intimacy drops noticeably, that is worth taking seriously rather than brushing off.
Pair the medication with the lifestyle that protects you. Protein, strength training, sleep, and social connection are not optional. They are how your brain keeps the parts of you that you do want to keep.
Plan the off-ramp. Most patients do not stay on the highest dose forever. A planned step-down, alongside a strengthened lifestyle baseline, is the sustainable shape.
Be honest about why you are on it. A GLP-1 for genuine metabolic disease or obesity with health risk is one conversation. A GLP-1 for cosmetic weight loss in someone with a healthy baseline is a different conversation, and the brain trade-offs are worth examining harder there.

Guidance from the clinic

"The food noise quieting on a GLP-1 can be life-changing for the right patient. The fact that the same circuits touch alcohol craving, anxiety, and mood is the most interesting story in metabolic medicine right now. The fact that they also touch desire, pleasure, and motivation is the part we cannot ignore. I prescribe these medications when the math is clearly in the patient's favor. I watch for the brain side every time, and I am honest with patients that we are still learning, together, what these drugs do."

Actionable Steps

If you are on a GLP-1 or thinking about starting.

Set a baseline. Before you start, write down where you stand on the things you care about: energy, mood, libido, pleasure from hobbies, sleep, ability to focus. 3 or 4 lines is enough to compare to later.
Name the goal. A specific number to move (A1c, ApoB, body composition) or a specific outcome (off a sleep apnea machine, more energy for the kids). The clearer the goal, the easier the titration conversation.
Protect muscle. Protein at every meal and resistance training at least twice a week. Muscle is what your brain and body need so the medication does not strip the wrong tissue.
Watch for emotional flattening. If pleasure, motivation, or libido drops noticeably in the first 3 months, raise it at your next visit. We can usually fix it by titrating.
Plan the off-ramp from the start. What does month 12 look like? What about month 24? A medication without a planned shape is a medication that slowly defines your life.

Key Takeaways

GLP-1s do more than quiet appetite; they appear to modulate the brain's reward and salience circuits more broadly.
The same mechanism that quiets food noise looks promising in alcohol, nicotine, gambling, and binge-eating disorders. Trials are underway.
Some patients report a flatter emotional baseline ("Ozempic personality") with reduced pleasure, motivation, or libido. The reports are common enough to warrant honest conversation rather than dismissal.
Phase III trials of semaglutide for Alzheimer's have not shown clinical benefit so far, though biomarker signals remain interesting. Earlier intervention and higher doses are being studied.
The practical lens is the same as any prescription: define the goal, pair with lifestyle that protects you, watch for the brain side, plan the off-ramp.

Scientific References

Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 384(11), 989-1002.
Klausen, M. K., et al. (2022). Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight, 7(19), e159863.
Brierley, D. I., et al. (2021). Central and peripheral GLP-1 systems independently suppress eating. Nature Metabolism, 3(2), 258-273.
Hsu, T. M., et al. (2018). A hippocampus to prefrontal cortex neural pathway inhibits food motivation through glucagon-like peptide-1 signaling. Molecular Psychiatry, 23(7), 1555-1565.
Mahapatra, M. K., et al. (2022). Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: A narrative review. Pharmaceutical Research, 39(6), 1233-1248.
Erbil, D., et al. (2019). GLP-1's role in neuroprotection: A systematic review. Brain Injury, 33(6), 734-749.
Athauda, D., et al. (2017). Exenatide once weekly versus placebo in Parkinson's disease (PD-LEAP). The Lancet, 390(10103), 1664-1675.

Fishtown Medicine | Articles

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start Your Intake

Frequently Asked Questions

Common Questions

"Ozempic personality" is the patient and social-media shorthand for a flatter emotional baseline some people report on GLP-1 medications: less pleasure from hobbies and food, lower libido, less motivation. Not everyone experiences it, and it is not yet formally characterized in research, but the reports are common and the underlying brain mechanism is plausible. Worth raising with your doctor if you notice it.

Early evidence suggests yes for some patients. Animal studies have shown GLP-1-like medications reduce alcohol intake, and patients on the medications often report the urge to drink slowly disappearing. Large randomized trials in alcohol use disorder are underway. Trials are also testing GLP-1s for nicotine, gambling, and binge-eating disorder. The data is promising but not yet the standard of care.

Not based on the current evidence. The largest Phase III trial of oral semaglutide in early Alzheimer's did not significantly slow cognitive decline. Some biomarker signals were interesting but not clinically meaningful. Whether GLP-1s can delay or prevent Alzheimer's if started much earlier is being studied. For now, lifestyle and the usual risk-factor modification (blood pressure, lipids, glucose, sleep) remain the strongest tools.

They are connected but not the same. Food noise is specifically the obsessive pull toward eating; quieting it is almost always experienced as positive. Emotional flattening is broader and refers to dampened reward and motivation across hobbies, intimacy, and life in general. Some patients experience the first without the second; some experience both. The line between them is where the careful clinical conversation lives.

Deep-Dive Questions

The salience network is the brain system that decides what is worth paying attention to. A 2025 imaging study at the University of Colorado Anschutz found that adolescents and young women on GLP-1 medications showed increased connectivity within the salience network within a few months. The clinical meaning is not yet clear, but it is consistent with the broader theme of these drugs modulating attention, craving, and reward.

The evoke and evoke+ trials of oral semaglutide in early Alzheimer's did not meet primary cognitive endpoints. Several explanations are being studied: the intervention may have come too late in the disease course; the dose may have been too low for the brain effect; or amyloid and tau pathology may need to be targeted in parallel. Earlier-intervention trials and higher-dose protocols are being designed.

The brain in adolescence is still developing, particularly the systems that decide what is rewarding and how the body regulates appetite. Imaging studies in teens with PMOS on GLP-1 medications have shown brain connectivity changes within months. Whether those changes persist after stopping the medication is one of the most important open questions in pediatric metabolic medicine. We use these drugs cautiously in adolescents and watch closely.

The same way I balance any medication: define the goal, weigh the alternatives, watch for both intended and unintended effects, and step down if the cost outweighs the benefit. For someone with significant metabolic disease, the cardiovascular and metabolic benefit is large, and a modest brain trade-off is worth the deal. For someone using a GLP-1 cosmetically with a healthy metabolic baseline, the calculus is closer, and the brain side weighs heavier.

Ready when you are

Start your intake

Dr. Ash reads every intake himself, and answers questions personally - usually within a few hours.

TL;DR30-second take

For the cardiometabolic side of the story, read GLP-1 medications beyond weight loss. For the broader prescribing lens, see how I decide to prescribe.

What we already knew: the "food noise" effect

The first surprise had less to do with weight than with quiet.

That fact alone predicted what came next.

What's emerging now: reward, craving, mood

If the medications quiet the urge to seek food, they might quiet other things people seek too.

The early evidence points that way, in ways that cut both directions.

The hopeful side

Alcohol. Early animal work in 2013 showed rodents on a GLP-1-like medication drank less alcohol. Human trials are now underway. Eli Lilly has a large clinical trial of tirzepatide for alcohol use disorder expected to read out within the next year. Patients on the medications informally report the same change: the nightly drink loses its pull.
Nicotine, gambling, binge eating. Trials are running across each of these. The mechanism is the same circuit: a reward system that has been hijacked by a substance or behavior, and a medication that quiets the hijack.
Mood and anxiety signals. Observational data and small studies have hinted that some patients feel less anxious, less compulsive, and a step less depressed. These signals are worth watching but preliminary, and randomized trials in psychiatric conditions are still early.
Long covid and inflammation. Trials of tirzepatide in long covid are underway on the hypothesis that chronic inflammation is part of the brain symptoms. We do not have the answer yet.

The cautionary side

Patients also report a less welcome version of the same effect. The blanket term in social media and patient communities is "Ozempic personality." It tends to mean some combination of:

A flatter baseline mood, with less spark and less spontaneous joy, though it stops short of depression.
Reduced pleasure from hobbies, music, food beyond hunger, or other reliable rewards.
Lower libido.
Less motivation to chase the things that used to feel meaningful.

How the brain effects probably work

We are still in the early innings on the mechanism, and several plausible explanations are likely true at the same time.

Direct brain action. GLP-1 receptors are densely concentrated in the hypothalamus, the brain stem, and parts of the reward circuit. Even though GLP-1 medications are large molecules, enough of them appears to reach the brain to act there.
Indirect brain action through the gut. Naturally produced GLP-1 talks to the brain through the vagus nerve. The same circuit modulates appetite, craving, mood, and cognition.
Inflammation, lowered. Some of the benefit may come from quieter system-wide inflammation. Brain inflammation has been implicated in cognitive decline, mood disorders, and the "brain fog" people describe after illness. GLP-1s appear to reduce some inflammatory markers.
Neuroplasticity changes. Early imaging studies have found increased connectivity in networks like the salience network (the system that decides what is worth paying attention to) in patients on these medications. The clinical meaning is still unclear.

What the big trials have and have not shown

Fishtown Medicine

A 90-minute conversation with Dr. Ash. A written plan you can actually follow.

Start your intake

The biggest scientific question of 2025 was whether GLP-1s could slow Alzheimer's disease. The answer, at least in the first large readout, was disappointing.

What I want you to know

When I prescribe a GLP-1, the conversation covers the whole life around the medication, well beyond the scale. A short version of how I think about it:

The medication is a tool. The job is to quiet a hijacked signal and let you do the work you could not do before. If you feel like a different person on it, in a direction you do not want, that is worth a conversation. We can usually titrate or step off.
Watch for emotional flattening. If pleasure from hobbies, music, food beyond hunger, or intimacy drops noticeably, that is worth taking seriously rather than brushing off.
Pair the medication with the lifestyle that protects you. Protein, strength training, sleep, and social connection are not optional. They are how your brain keeps the parts of you that you do want to keep.
Plan the off-ramp. Most patients do not stay on the highest dose forever. A planned step-down, alongside a strengthened lifestyle baseline, is the sustainable shape.
Be honest about why you are on it. A GLP-1 for genuine metabolic disease or obesity with health risk is one conversation. A GLP-1 for cosmetic weight loss in someone with a healthy baseline is a different conversation, and the brain trade-offs are worth examining harder there.

Guidance from the clinic

Actionable Steps

If you are on a GLP-1 or thinking about starting.

Set a baseline. Before you start, write down where you stand on the things you care about: energy, mood, libido, pleasure from hobbies, sleep, ability to focus. 3 or 4 lines is enough to compare to later.
Name the goal. A specific number to move (A1c, ApoB, body composition) or a specific outcome (off a sleep apnea machine, more energy for the kids). The clearer the goal, the easier the titration conversation.
Protect muscle. Protein at every meal and resistance training at least twice a week. Muscle is what your brain and body need so the medication does not strip the wrong tissue.
Watch for emotional flattening. If pleasure, motivation, or libido drops noticeably in the first 3 months, raise it at your next visit. We can usually fix it by titrating.
Plan the off-ramp from the start. What does month 12 look like? What about month 24? A medication without a planned shape is a medication that slowly defines your life.

Key Takeaways

GLP-1s do more than quiet appetite; they appear to modulate the brain's reward and salience circuits more broadly.
The same mechanism that quiets food noise looks promising in alcohol, nicotine, gambling, and binge-eating disorders. Trials are underway.
Some patients report a flatter emotional baseline ("Ozempic personality") with reduced pleasure, motivation, or libido. The reports are common enough to warrant honest conversation rather than dismissal.
Phase III trials of semaglutide for Alzheimer's have not shown clinical benefit so far, though biomarker signals remain interesting. Earlier intervention and higher doses are being studied.
The practical lens is the same as any prescription: define the goal, pair with lifestyle that protects you, watch for the brain side, plan the off-ramp.